Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes

Toxicological Sciences

Volumn 91, Issue 2, 2006, Pages 356-364

  Liu, Yong ^a,b   Zhang, Jiang Wei ^a,b   Li, Wei ^a,b   Ma, Hong ^c   Sun, Jie ^d   Deng, Mai Cun ^a   Yang, Ling ^a,e  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c LIAONING NORMAL UNIVERSITY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e NONE   (China)

Author keywords

Cytochrome P450; Ginseng drug interactions; Ginsenosides; Intestinal metabolites

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GINSENG EXTRACT; GINSENOSIDE; ISOPROTEIN; PROTOPANAXADIOL;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE; LIVER MICROSOME METABOLISM; PROTEIN EXPRESSION; PROTEIN METABOLISM; STRUCTURE ANALYSIS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GINSENOSIDES; HUMANS; INTESTINES; MICROSOMES, LIVER; MODELS, BIOLOGICAL; RATS; SAPOGENINS; TRITERPENES;

PANAX GINSENG;

EID: 33744799726     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfj164     Document Type: Article

References (38)

1. Akao, T., Kanaoka, M., and Kobashi, K. (1998). Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration - measurement of compound K by enzyme immunoassay. Biol. Pharm. Bull. 21, 245-249.
2. Attele, A. S., Wu, J. A., and Yuan, C. S, (1999). Ginseng pharmacology: Multiple constituents and multiple actions. Biochem. Pharmacol. 58, 1685-1693.
3. Bae, E. A., Park, S. Y., and Kim, D. H. (2000). Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol. Pharm. Bull. 23, 1481-1485.
4. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815-832.
5. Copeland, R. A. (2000). Enzymes: A practical introduction to structure, mechanism, and data analysis. (R. A. Copeland, Ed.), 2nd ed. Wiley-VCH, New York.
6. Chang, T. K., Chen, J., and Benetton, S. A. (2002). In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos. 30, 378-384.
7. Dahan, A., and Altman, H. (2004). Food-drug interaction: Grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur. J. Clin. Nutr. 58, 1-9.
8. Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095.
9. Donovan, J. L., DeVane, C. L., Chavin, K. D., Taylor, R. M., and Markowitz, J. S. (2003). Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab. Dispos. 31, 519-522.
10. Eagling, V. A., Tjia, J. F., and Back, D. J. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45, 107-114.
11. Ekins, S., Ring, B. J., Grace, J., McRobie-Belle, D. J., and Wrighton, S. A. (2000). Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Methods 44, 313-324.
12. Estabrook, R. (1999). An introduction to the cytochrome P450s. Mol. Aspects Med. 20, 5-12.
13. Goldstein, J. A., and de Morais, S. M. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299.
14. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., and Ang, C. Y. (2002). Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 72, 276-287.
15. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., and Ang, C. Y. (2005). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, panax ginseng and ginkgo biloba. Drugs Aging 22, 525-539.
16. Harkey, M. R., Henderson, G. L., Gershwin, M. E., Stem, J. S., and Hackman, R. S. (2001). Variability in commercial ginseng products: An analysis of 25 preparations. Am. J. Clin. Nutr. 73, 1101-1106.
17. Hasegawa, H. (2004). Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid. J. Pharmacol. Sci. 95, 153-157.
18. Hasegawa, H., Sung, J. H., Matsumiya, S., and Uchiyama, M. (1996). Main ginseng metabolites formed by intestinal bacteria. Planta Med. 62, 453-457.
19. Hasegawa, H., Suzuki, R., Nagaoka, T., Tezuka, Y., Kadota, S., and Saiki, I. (2002). Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol. Pharm. Bull. 25, 861-866.
20. Henderson, G. L., Harkey, M. R., Gershwin, M. E., Hackman, R. M., Stern, J. S., and Stresser, D. M. (1999). Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 65, PL209-PL214.
21. Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 25, 193-200.
22. Janetzky, K., and Morreale, A. P. (1997). Probable interaction between warfarin and ginseng. Am. J. Health Syst. Pharm. 54, 692-693.
23. Jiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., and McLachlan, A. J. (2004). Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 57, 592-599.
24. Liu, Y., Li, W., Li, P., Deng, M. C., Yang, S. L., and Yang, L. (2004). The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity. Biol. Pharm. Bull. 27, 1555-1560.
25. Liu, Y., Ma, H., Zhang, J. W., Deng, M. C., and Yang, L. (2006). Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes. Planta Med. 72, 126-131.
26. Lowry, O. H., Roseborough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
27. McKillop, D., Wild, M. J., Butters, C. J., and Simcock, C. (1998). Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 28, 845-853.
28. Obach, R. S., Zhang, Q. Y., Dunbar, D., and Kaminsky, L. S. (2001). Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab. Dispos. 29, 347-352.
29. Odani, T., Tanizawa, H., and Takino, Y. (1983a). Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. II. The absorption, distribution and excretion of ginsenoside Rg1 in the rat. Chem. Pharm. Bull. 31, 292-298.
30. Odani, T., Tanizawa, H., and Takino, Y. (1983b). Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. III. The absorption, distribution and excretion of ginsenoside Rb1 in the rat. Chem. Pharm. Bull. 31, 1059-1066.
31. Paine, M. F., Criss, A. B., and Watkins, P. B. (2004). Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab. Dispos. 32, 1146-1153.
32. Paine, M. F., Criss, A. B., and Watkins, P. B. (2005). Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J. Pharmacol. Exp. Ther. 312, 1151-1160.
33. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
34. Shu, Y., Cheng, Z. N., Liu, Z. Q., Wang, L. S., Zhu, B., Huang, S. L., Ou-Yang, D. S., and Zhou, H. H. (2001). Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol. Sin. 22, 283-288.
35. Smith, M., Lin, K. M., and Zheng, Y. P. (2001). An open trial of nifedipine-herb interactions: Nifedipine with St John's wort, ginseng or ginkgo biloba [abstract]. Clin. Pharmacol. Ther. 69, P86.
36. Tawab, M. A., Bahr, U., Karas, M., Wurglics, M., and Schubert-Zsilavecz, M. (2003). Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos. 31, 1065-1071.
37. Xu, Q. F., Fangm, X. L., and Chen, D. F. (2003). Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J. Ethnopharmacol. 84, 187-192.
38. Zhang, Q. Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., and Kaminsky, L. S. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27, 804-809.